Allitia is 20-year veteran in the fight against neurologic disease. As a clinician-researcher at Harvard, she worked on treatments for ALS and subsequently held leadership positions at J&J, Novartis, and GSK across R&D and Medical Affairs. Allitia has modeled clinical trial outcomes in AD, developed advocacy outreach strategies for multiple disease areas, designed PhIV differentiation studies and registries both for market access and for differentiation, and stood up Expanded Access Programs. Allitia was the Global Medical Affairs lead for the first FDA-approved psychedelic treatment for TRD, Spravato. She wants to change the world for patients suffering from CNS disorders.